Stockscreener 앱 받기
7.93
2.85%
0.22
시간 외 거래:
7.89
-0.04
-0.50%
전일 마감가:
$7.71
열려 있는:
$7.8
하루 거래량:
114.38K
Relative Volume:
3.66
시가총액:
$37.67M
수익:
$5.75M
순이익/손실:
$-38.96M
주가수익비율:
-0.6359
EPS:
-12.47
순현금흐름:
$-32.63M
1주 성능:
+13.61%
1개월 성능:
+21.24%
6개월 성능:
+16.28%
1년 성능:
+11.38%
1일 변동 폭
$7.80
$8.39
1주일 범위
$6.52
$8.79
52주 변동 폭
$4.21
$9.25
칼라 파마슈티컬스 Stock (KALA) Company Profile
명칭
Kala Bio Inc
전화
781-996-5252
주소
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
KALA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
7.93 | 37.67M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
621.29 | 37.15B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.28 | 30.22B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.79 | 27.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
칼라 파마슈티컬스 Stock (KALA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-03-30 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-09-14 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-07-23 | 개시 | Northland Capital | Outperform |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2020-05-27 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-09 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | 개시 | Jefferies | Buy |
모두보기
칼라 파마슈티컬스 주식(KALA)의 최신 뉴스
Baker Bros. Advisors LP Increases Stake in Kala Bio Inc - GuruFocus.com
KALA BIO announces $10.75M private placement - MSN
Baker Bros. Advisors buys $2 million in Kala Bio shares By Investing.com - Investing.com Nigeria
Baker Bros. Advisors buys $2 million in Kala Bio shares - Investing.com
Kala Bio raises $10.75 million in private placement By Investing.com - Investing.com Canada
KALA BIO Announces Private Placement Agreement with Institutional Investors - Defense World
KALA BIO Secures $10.75 Million in Private Placement to Advance Eye Disease Treatments - Tandav Media
Kala Bio raises $10.75 million in private placement - Investing.com India
KALA Bio Secures $10.75 Million for Eye Disease Treatments: What’s Next for the Biopharma Stock? - Tandav Media
KALA BIO Announces $10,750,000 Private Placement - GlobeNewswire
Global Engine Group Holding Limited Acquires 22.5% Stake in Corpotech Holdings Limited, a Hong Kong Data Centre Operator - The Manila Times
KALA BIO Secures $10.75M Investment from Major Funds, Extends Cash Runway for Key Eye Treatment Trial - StockTitan
BioAtla announces registered direct offering to advance two mid-stage clinical programs, shares fall - Seeking Alpha
KALA BIO (KALA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Zacks Investment Research
Tracking Baker Brothers Portfolio – Q3 2024 Update - Seeking Alpha
Kala Bio (LTS:0JQ2) EV-to-Revenue : (As of Nov. 30, 2024) - GuruFocus.com
KALAKALA BIO, Inc. Latest Stock News & Market Updates - StockTitan
FTC Solar Announces Reverse Stock Split - The Manila Times
KALA BIO to Present at Piper Sandler Healthcare Conference, Showcasing Eye Disease Pipeline | KALA Stock News - StockTitan
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
2024 Pharmaceutical Executive APEX Award Winners - Pharmaceutical Executive
Kala Pharmaceuticals Announces IND Submission of its MPP-Formulated Loteprednol Etonbonate (LE-MPP) for Post-Cataract Surgery - Marketscreener.com
Kala Pharmaceuticals retains stock target with Buy rating on trial progress - Investing.com India
60 Degrees Pharmaceuticals’ (SXTP) Neutral Rating Reaffirmed at HC Wainwright - Defense World
Walt Disney (NYSE:DIS) Price Target Raised to $130.00 - Defense World
KALA BIO’s (KALA) Buy Rating Reaffirmed at HC Wainwright - Defense World
ADAR1 Capital Management, LLC Increases Stake in Kala Bio Inc - GuruFocus.com
KALA BIO, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Kala Bio Advances PCED Treatment Amid Financial Update - TipRanks
KALA BIO: Q3 Earnings Snapshot - mySA
KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
KALA BIO Reports $49.2M Cash Position, Advances Phase 2b PCED Trial Despite Wider Losses | KALA Stock News - StockTitan
Super Micro slumps as weak forecast, annual report uncertainty fuel investor angst - AOL
Standard Life Private Equity Trust (LON:SLPE) Trading Down 1.5% – Here’s Why - Defense World
Travis Kalanick | Biography, Uber, & Facts - Britannica
Persistent Corneal Epithelial Defects Pipeline 2024: Clinical - openPR
Persistent Epithelial Defect Market Size is Set for Rapid Growth - openPR
Sunrun (NASDAQ:RUN) Trading Down 5.8% on Insider Selling - Defense World
MPTI Stock Trades Near 52-Week High: Is It Still Worth Buying? - MSN
Here's What Makes Cabot Stock a Solid Choice Right Now - MSN
Here's Why Welltower Stock is an Apt Portfolio Pick for Now - MSN
Broadcom Stock Hits Buy Point On Product News Ahead Of Major Conference - MSN
KALA BIO (KALA) Moves to Strong Buy: Rationale Behind the Upgrade - Yahoo Finance
Dynatrace Shows Improved Relative Strength; Still Shy Of Benchmark - MSN
Brookdale Bets Big With $610M Acquisitions Amid Debt Refinancing - MSN
Toast, Inc. (TOST) is Attracting Investor Attention: Here is What You Should Know - MSN
Here's Why Freeport-McMoRan Stock Soared in September - AOL
Oppenheimer Initiates Coverage of Euronet Worldwide (EEFT) with Outperform Recommendation - MSN
Transparency-One’s Kala Hanson Named Recipient of 2024 Women in Supply Chain Award - Yahoo Finance
AAM Names John A. Murphy as CEO - Pharmaceutical Executive
KALA BIO director resigns from board and committees By Investing.com - Investing.com Australia
칼라 파마슈티컬스 (KALA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
칼라 파마슈티컬스 주식 (KALA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bazemore Todd | SEE REMARKS |
Jun 26 '24 |
Sale |
4.75 |
4,653 |
22,102 |
83,040 |
| Kharabi Darius | CHIEF BUSINESS OFFICER |
Jun 26 '24 |
Sale |
4.75 |
5,158 |
24,500 |
59,728 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Jun 26 '24 |
Sale |
4.75 |
4,163 |
19,774 |
60,187 |
| Iwicki Mark T | CHIEF EXECUTIVE OFFICER |
Jun 26 '24 |
Sale |
4.75 |
15,168 |
72,048 |
263,755 |
| Brazzell Romulus K | SEE REMARKS |
Jun 26 '24 |
Sale |
4.75 |
5,489 |
26,073 |
83,982 |
| Bazemore Todd | SEE REMARKS |
May 31 '24 |
Sale |
6.09 |
2,093 |
12,746 |
87,693 |
| Kharabi Darius | CHIEF BUSINESS OFFICER |
May 31 '24 |
Sale |
6.09 |
231 |
1,407 |
64,886 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
May 31 '24 |
Sale |
6.09 |
1,786 |
10,877 |
64,350 |
| Brazzell Romulus K | SEE REMARKS |
May 31 '24 |
Sale |
6.09 |
2,002 |
12,192 |
89,471 |
| Iwicki Mark T | CHIEF EXECUTIVE OFFICER |
May 31 '24 |
Sale |
6.09 |
7,392 |
45,017 |
278,923 |
0.60%
2.24%
자본화:
|
볼륨(24시간):